Allison Bratzel
Stock Analyst at Piper Sandler
(4.58)
# 229
Out of 4,876 analysts
39
Total ratings
63.33%
Success rate
23.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Overweight | $14 → $22 | $9.33 | +135.80% | 2 | Jun 2, 2025 | |
| TYRA Tyra Biosciences | Assumes: Overweight | $33 | $9.10 | +262.64% | 1 | May 21, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $140 → $115 | $36.52 | +214.90% | 1 | Mar 17, 2025 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $4 → $6 | $3.65 | +64.38% | 1 | Mar 14, 2025 | |
| INZY Inozyme Pharma | Maintains: Overweight | $30 → $23 | $3.99 | +476.44% | 1 | Mar 11, 2025 | |
| ENGN enGene Holdings | Initiates: Overweight | $26 | $3.66 | +610.38% | 1 | Feb 18, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $620 → $725 | $560.14 | +29.43% | 13 | Jan 7, 2025 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $12 → $22 | $14.77 | +48.95% | 2 | Nov 14, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $15 → $23 | $19.48 | +18.07% | 2 | Nov 14, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $65 → $62 | $39.80 | +55.78% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $42 | $35.81 | +17.29% | 3 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $11.39 | +93.15% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $2.12 | +88.68% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $4.72 | +323.73% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $3.61 | +454.02% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 | $68.37 | +46.26% | 2 | Feb 8, 2023 |
Replimune Group
Jun 2, 2025
Maintains: Overweight
Price Target: $14 → $22
Current: $9.33
Upside: +135.80%
Tyra Biosciences
May 21, 2025
Assumes: Overweight
Price Target: $33
Current: $9.10
Upside: +262.64%
Ultragenyx Pharmaceutical
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $36.52
Upside: +214.90%
Akebia Therapeutics
Mar 14, 2025
Maintains: Overweight
Price Target: $4 → $6
Current: $3.65
Upside: +64.38%
Inozyme Pharma
Mar 11, 2025
Maintains: Overweight
Price Target: $30 → $23
Current: $3.99
Upside: +476.44%
enGene Holdings
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $3.66
Upside: +610.38%
argenx SE
Jan 7, 2025
Maintains: Overweight
Price Target: $620 → $725
Current: $560.14
Upside: +29.43%
Travere Therapeutics
Nov 14, 2024
Maintains: Neutral
Price Target: $12 → $22
Current: $14.77
Upside: +48.95%
Rigel Pharmaceuticals
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $19.48
Upside: +18.07%
Ionis Pharmaceuticals
Nov 14, 2024
Maintains: Overweight
Price Target: $65 → $62
Current: $39.80
Upside: +55.78%
Oct 15, 2024
Maintains: Overweight
Price Target: $28 → $42
Current: $35.81
Upside: +17.29%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $11.39
Upside: +93.15%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $2.12
Upside: +88.68%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $4.72
Upside: +323.73%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $3.61
Upside: +454.02%
Feb 8, 2023
Maintains: Overweight
Price Target: $100
Current: $68.37
Upside: +46.26%